Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment—A Systematic Review

Rammos, Aidonis; Meladinis, Vasileios; Vovas, Georgios; Patsouras, Dimitrios

doi:10.1155/2017/2874902

Cited by 38 publications

(68 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In all studied referral cases, both morphological and functional parameter of restrictive cardiomyopathy and constrictive cardiomyopathy are similar apart from septal bounce which is diagnostic for constrictive pericarditis and detected on MRI using a real-time imaging sequence in the short-axis plan and thickened enhancing or non-enhancing pericardium and this point is superior assessed by MRI than echo. Our findings are a closer match with study conducted by Rammos et al [21] that use the respiratory-related ventricular coupling to differentiate patients with constrictive pericarditis and RCM.…”

Section: Discussionsupporting

confidence: 91%

Delayed myocardial enhancement in children with different types of cardiomyopathy: a diagnostic and prognostic tool

Elfadl

Mogy

Abouelkeir

et al. 2019

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background: The pattern of late gadolinium enhancement (LGE) in cardiomyopathy is quite different in children compared to adults. In addition, the data about LGE imaging in children are still restricted, so the goal was to study the role of cardiac magnetic resonance (CMR) with different techniques, including LGE images in diagnosis and evaluation of different types of cardiomyopathy in children. Results: In group A (enhancement group), LVEDV 146.2 (144) ml, indexed LVEDV 81.8 (195) ml, LVESV 50 (357) ml, indexed LVESV 47.5 (243) ml, and LVEF 36% (64%), and a major adverse effect was found in 12 out of 15 cases (80%). However, in group B (non-enhancement group), the results were LVEDV 72 (303) ml, indexed LVEDV 75 (318) ml, LVESV 30 (220) ml, indexed LVESV 37.1 (189) ml, and LVEF 45.79% (65%), and a major adverse cardiac effect was found in 2 out of 16 cases (12.5%). The LVEF was lower, and LV volume indices including LVEDV and LVESV were higher in patients with LGE compared to those without LGE with a statistically significant difference (p value = 0.001, p value = 0.003, and p value = 0.005, respectively). Furthermore, it was also found that a major adverse effect occurs with higher incidence in enhancement cases (92%) as compared to non-enhancement cases (12.5%) with a statistically significant difference (p value ≤ 0.001). LGE was found in 15 cases out of 31 cases (48.4%); however, the remaining 13 cases had no contrast study. Conclusion: Cardiac MRI can be considered as an important non-invasive imaging modality, not only for assessment but also for differentiation between ischemic and non-ischemic cardiomyopathy in the pediatric age group. Using its different techniques allows a better assessment of morphologic and functional parameters in cardiomyopathy. Moreover, the late gadolinium enhancement is regarded as a promising non-invasive tool in the detection and quantification of myocardial scars. That is considered of high importance in diagnosis, categorization, and detection of etiology in most cases of different types of cardiomyopathy, in addition to risk stratification that can be an essential step in patient management.

show abstract

Section: Discussionsupporting

confidence: 91%

Delayed myocardial enhancement in children with different types of cardiomyopathy: a diagnostic and prognostic tool

Elfadl

Mogy

Abouelkeir

et al. 2019

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

show abstract

“…The clinical diagnosis of cardiomyopathy has been established by electrocardiography, echography, and MRI according to usual European recommendations in 14 expert centers in France …”

Section: Methodsmentioning

confidence: 99%

FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype‐phenotype correlations

et al. 2019

View full text Add to dashboard Cite

Pathogenic variants in FLNC encoding filamin C have been firstly reported to cause myopathies, and were recently linked to isolated cardiac phenotypes. Our aim was to estimate the prevalence of FLNC pathogenic variants in subtypes of cardiomyopathies and to study the relations between phenotype and genotype. DNAs from a cohort of 1150 unrelated index‐patients with isolated cardiomyopathy (700 hypertrophic, 300 dilated, 50 restrictive cardiomyopathies, and 100 left ventricle non‐compactions) have been sequenced on a custom panel of 51 cardiomyopathy disease‐causing genes. An FLNC pathogenic variant was identified in 28 patients corresponding to a prevalence ranging from 1% to 8% depending on the cardiomyopathy subtype. Truncating variants were always identified in patients with dilated cardiomyopathy, while missense or in‐frame indel variants were found in other phenotypes. A personal or family history of sudden cardiac death (SCD) was significantly higher in patients with truncating variants than in patients carrying missense variants (P = .01). This work reported the first observation of a left ventricular non‐compaction associated with a unique probably causal variant in FLNC which highlights the role of FLNC in cardiomyopathies. A correlation between the nature of the variant and the cardiomyopathy subtype was observed as well as with SCD risk.

show abstract

“…Interestingly, ATTRwt CA has been proved via 99mTc-DPD scintigraphy to represent 13% of patients with Heart Failure with a Preserved Ejection Fraction (HFpEF), in a sample of 120 patients over 60 years old [ 13 ]. CA is the primary cause of restrictive cardiomyopathy (RCM) [ 14 , 15 ]. In summary, cardiac amyloidosis’ frequency among HF patients is increasingly being acknowledged by clinicians and researchers alike, as can be observed from its inclusion in the novel MOGES classification of cardiomyopathies [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers

Kyriakou

Mouselimis

Tsarouchas

et al. 2018

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundCardiac Amyloidosis (CA) pertains to the cardiac involvement of a group of diseases, in which misfolded proteins deposit in tissues and cause progressive organ damage. The vast majority of CA cases are caused by light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). The increased awareness of these diseases has led to an increment of newly diagnosed cases each year.MethodsWe performed multiple searches on MEDLINE, EMBASE and the Cochrane Database of Systematic Reviews. Several search terms were used, such as “cardiac amyloidosis”, “diagnostic modalities cardiac amyloidosis” and “staging cardiac amyloidosis”. Emphasis was given on original articles describing novel diagnostic and staging approaches to the disease.ResultsImaging techniques are indispensable to diagnosing CA. Novel ultrasonographic techniques boast high sensitivity and specificity for the disease. Nuclear imaging has repeatedly proved its worth in the diagnostic procedure, with efforts now focusing on standardization and quantification of amyloid load. Because the latter would be invaluable for any staging system, those spearheading research in magnetic resonance imaging of the disease are also trying to come up with accurate tools to quantify amyloid burden. Staging tools are currently being developed and validated for ATTR CA, in the spirit of the acclaimed Mayo Staging System for AL.ConclusionCardiac involvement confers significant morbidity and mortality in all types of amyloidosis. Great effort is made to reduce the time to diagnosis, as treatment in the initial stages of the disease is tied to better prognosis. The results of these efforts are highly sensitive and specific diagnostic modalities that are also reasonably cost effective.

show abstract

Restrictive Cardiomyopathies: The Importance of Noninvasive Cardiac Imaging Modalities in Diagnosis and Treatment—A Systematic Review

Cited by 38 publications

References 102 publications

Delayed myocardial enhancement in children with different types of cardiomyopathy: a diagnostic and prognostic tool

Delayed myocardial enhancement in children with different types of cardiomyopathy: a diagnostic and prognostic tool

FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype‐phenotype correlations

Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers

Contact Info

Product

Resources

About